In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis.
Authors: de Grauw J C, van de Lest C H A, Brama P A J, Rambags B P B, van Weeren P R
Journal: Equine veterinary journal
Summary
# Editorial Summary De Grauw and colleagues investigated meloxicam's ability to modulate the inflammatory and catabolic cascade in acutely inflamed equine joints, using lipopolysaccharide-induced synovitis as an experimental model. Six horses received either meloxicam (0.6 mg/kg orally once daily) or placebo beginning two hours after LPS injection, with clinical assessments and synovial fluid sampling conducted over seven days. The NSAID significantly reduced lameness scores at 8 and 24 hours post-injection and suppressed key inflammatory mediators—prostaglandin E₂ and substance P at 8 hours, and bradykinin at 24 hours—whilst simultaneously lowering matrix metalloproteinase activity and cartilage biomarker concentrations (glycosaminoglycans, collagen II cleavage fragments and carboxypropeptide) at 24 hours. These findings demonstrate that early meloxicam administration limits both the acute inflammatory response and downstream cartilage catabolism in synovitis, suggesting its use within the critical early inflammatory window may reduce long-term degenerative sequelae. For equine practitioners, this supports prompt NSAID intervention at the first signs of acute joint inflammation, potentially mitigating career-altering cartilage damage before irreversible changes become established.
Read the full abstract on PubMed
Practical Takeaways
- •Early oral meloxicam treatment (starting at 2 hours post-injury) effectively reduces clinical signs of acute joint inflammation and may limit cartilage damage in synovitis cases
- •Meloxicam's anti-inflammatory effect extends beyond pain relief to suppress key inflammatory mediators and reduce matrix metalloproteinase activity that drives cartilage breakdown
- •Consider meloxicam as a first-line treatment for acute synovitis to address both immediate clinical signs and underlying inflammatory damage to articular cartilage
Key Findings
- •Meloxicam significantly reduced lameness at 8 and 24 hours post-LPS injection compared to placebo
- •Meloxicam suppressed synovial fluid prostaglandin E2 and substance P at 8 hours, and bradykinin at 24 hours
- •General MMP activity was significantly lower in meloxicam-treated joints at 8 and 24 hours
- •Cartilage biomarkers (GAG, C2C, CPII) were significantly reduced in meloxicam-treated joints at 24 hours post-injection